Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets
- PMID: 28674979
- DOI: 10.1007/978-3-319-57193-5_4
Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets
Abstract
Huntington's disease (HD) is a tandem repeat disorder involving neurodegeneration and a complex combination of symptoms. These include psychiatric symptoms, cognitive deficits culminating in dementia, and the movement disorder epitomised by motor signs such as chorea. HD is caused by a CAG repeat expansion encoding an extended tract of the amino acid glutamine in the huntingtin protein. This polyglutamine expansion appears to induce a 'change of function', possibly a 'gain of function', in the huntingtin protein, which leads to various molecular and cellular cascades of pathogenesis. In the current review, we will briefly describe these broader aspects of HD pathogenesis, but will then focus on specific aspects where there are substantial bodies of experimental evidence, including oxidative stress, mitochondrial dysfunction, glutamatergic dysfunction and neuroinflammation. Furthermore, we will review recent preclinical therapeutic approaches targeting some of these pathogenic pathways, their clinical implications and future directions.
Keywords: Cerebral cortex; Cognitive symptoms; Dementia; Huntington’s disease; Movement disorder; Neurodegeneration; Polyglutamine disease; Psychiatric illness; Striatum; Tandem repeat disorder.
Similar articles
-
Molecular Pathogenesis in Huntington's Disease.Biochemistry (Mosc). 2018 Sep;83(9):1030-1039. doi: 10.1134/S0006297918090043. Biochemistry (Mosc). 2018. PMID: 30472941 Review.
-
Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.J Neurosci Res. 2019 Nov;97(11):1455-1468. doi: 10.1002/jnr.24492. Epub 2019 Jul 15. J Neurosci Res. 2019. PMID: 31304621 Review.
-
Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Epub 2012 May 24. Neuroscience. 2013. PMID: 22633949 Review.
-
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.Hum Mol Genet. 2018 May 1;27(9):1545-1555. doi: 10.1093/hmg/ddy061. Hum Mol Genet. 2018. PMID: 29462355 Free PMC article.
-
The role of mitochondrial dysfunction in Huntington's disease: Implications for therapeutic targeting.Biomed Pharmacother. 2025 Feb;183:117827. doi: 10.1016/j.biopha.2025.117827. Epub 2025 Jan 23. Biomed Pharmacother. 2025. PMID: 39854819 Review.
Cited by
-
Mitochondria in Huntington's disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies.Neural Regen Res. 2023 Jul;18(7):1472-1477. doi: 10.4103/1673-5374.360289. Neural Regen Res. 2023. PMID: 36571344 Free PMC article. Review.
-
Mitochondrial Dysfunction in Repeat Expansion Diseases.Antioxidants (Basel). 2023 Aug 10;12(8):1593. doi: 10.3390/antiox12081593. Antioxidants (Basel). 2023. PMID: 37627588 Free PMC article. Review.
-
Spermatozoan Metabolism as a Non-Traditional Model for the Study of Huntington's Disease.Int J Mol Sci. 2022 Jun 28;23(13):7163. doi: 10.3390/ijms23137163. Int J Mol Sci. 2022. PMID: 35806166 Free PMC article. Review.
-
Protein Misfolding and ER Stress in Huntington's Disease.Front Mol Biosci. 2019 Apr 3;6:20. doi: 10.3389/fmolb.2019.00020. eCollection 2019. Front Mol Biosci. 2019. PMID: 31001537 Free PMC article. Review.
-
Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases.Molecules. 2024 Dec 2;29(23):5700. doi: 10.3390/molecules29235700. Molecules. 2024. PMID: 39683859 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical